Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Spark Capital Advisors(India) Private Limited
$35.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Aurobindo Pharma Ltd Receives USFDA Approvals For Tamsulosin HCL Capsules And Clindamycin Palmitate Hydrochloride For Oral Solution (Pediatric)


Saturday, 4 May 2013 01:02am EDT 

Aurobindo Pharma Ltd announced that the Company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Tamsulosin Hydrochloride Capsules USP 0.4mg (ANDA 202433) and Clindamycin Palmitate Hydrochloride for Oral Solution USP(Pediatric), 75mg (base)/5mL (ANDA 202409). The products will be launched soon. Tamsulosin Hydrochloride Capsules USP 0.4mg is the generic equivalent of Boehringer Ingelheim Pharmaceuticals’ Flomax Capsules, 0.4mg and is indicated for the treatment of symptoms of an enlarged prostate (Benign Prostatic Hyperplasia - BPH) in men. The market size of the product is estimated to be USD244 Million for the twelve months ending September 2012 according to IMS. 

Company Quote

868.3
16.2 +1.90%
17 Sep 2014